Invention Grant
- Patent Title: Procaspase 3 activation by combination therapy
-
Application No.: US17144926Application Date: 2021-01-08
-
Publication No.: US11833147B2Publication Date: 2023-12-05
- Inventor: Paul J. Hergenrother , Rachel C. Botham , Timothy M. Fan , Mark J. Gilbert , Michael K. Handley , Howard S. Roth , Theodore M. Tarasow
- Applicant: The Board of Trustees of the University of Illinois , Vanquish Oncology, Inc.
- Applicant Address: US IL Urbana
- Assignee: Vanquish Oncology, Inc.,The Board of Trustees of the University of Illinois
- Current Assignee: Vanquish Oncology, Inc.,The Board of Trustees of the University of Illinois
- Current Assignee Address: US IL Champaign; US IL Urbana
- Agency: Haukaas Fortius PLLC
- Agent Michael Haukaas
- Main IPC: A61K31/495
- IPC: A61K31/495 ; A61K33/243 ; A61K9/08 ; A61K31/138 ; A61K31/282 ; A61K31/337 ; A61K31/496 ; A61K31/553 ; A61K31/704 ; A61K31/7048 ; A61K33/24 ; A61K38/05 ; A61K45/06 ; A61K47/10 ; A61K9/00 ; A61K9/20 ; A61K9/48

Abstract:
The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
Public/Granted literature
- US20210128551A1 PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY Public/Granted day:2021-05-06
Information query